Objective and subjective measures of dalfampridine efficacy in clinical practice

BACKGROUND: Multiple sclerosis affects mobility in over 80% of patients. Dalfampridine is the only approved treatment for walking impairment in multiple sclerosis. We assessed dalfampridine utilization in our practice and investigated response using timed 25 foot walk (T25FW) improvement and a patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Klineova, Sylvia, Farber, Rebecca, Friedman, Joshua, Farrell, Colleen, Lublin, Fred D, Krieger, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6077903/
https://www.ncbi.nlm.nih.gov/pubmed/30090641
http://dx.doi.org/10.1177/2055217318786742

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6077903/
https://www.ncbi.nlm.nih.gov/pubmed/30090641
http://dx.doi.org/10.1177/2055217318786742

Ejemplares similares